PT  - JOURNAL ARTICLE
AU  - Qiang Zeng
AU  - Yong-zhe Li
AU  - Gang Huang
AU  - Wei Wu
AU  - Sheng-yong Dong
AU  - Yang Xu
TI  - Mortality of COVID-19 is Associated with Cellular Immune Function Compared to Immune Function in Chinese Han Population
AID  - 10.1101/2020.03.08.20031229
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.03.08.20031229
4099  - http://medrxiv.org/content/early/2020/03/13/2020.03.08.20031229.short
4100  - http://medrxiv.org/content/early/2020/03/13/2020.03.08.20031229.full
AB  - In December 2019, novel coronavirus (SARS-CoV-2) infected pneumonia occurred in Wuhan, China. The number of cases has increased rapidly but information on the clinical characteristics of SARS-CoV-2 pneumonia compared to normal controls in Chinese Han population is limited. Our objective is to describe the clinical characteristics of SARS-CoV-2 pneumonia compared to normal controls in the Chinese Han population. In this case series of 752 patients, the full spectrum of cases is described. Fever was present in 86-90% of the patients. The second most common symptom was cough (49.1-51.0%), fatigue (25.2-27.1%), sputum (20.0-23.1%), and headache (9.8-11.1%). the mortality rate is 4.6% in Wuhan, 1.9% in Beijing, and 0.9% in Shanghai. Our findings showed that the levels of lymphocytes were 0.8(IQR, 0.6-1.1)109/L in Wuhan, 1.0(IQR, 0.7-1.4)109/L in Beijing, and 1.1 (IQR, 0.8-1.5) 109/L in Shanghai before admission to hospitals, respectively, indicating that cellular immune function might relate to the mortality. Based on the reference ranges of normal Chinese Han population and the data of the critically ill patients we have observed, it is recommended that reference ranges of people at high risk of COVID-19 infection are CD3+ lymphocytes below 900 cells/mm3, CD4+ lymphocytes below 500 cells/mm3, and CD8+ lymphocytes below 300 cells/mm3.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was supported by research grants from National Natural Science Foundation of China (Grant No. 81830052）and Shanghai Key Laboratory of Molecular Imaging（18DZ2260400）Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesthe availability of all data referred to in the manuscript is avalable